{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:03Z","timestamp":1794047463123,"version":"4.8.0"},"reference-count":119,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Three major directions for the global progress of adeno-associated virus (AAV) vectors for gene therapies (GT) are analyzed: 1) engineering vectors to increase transgene expression; 2) aligning interests of the health system with costs and challenges for the pharmaceutical industry; and 3) refining patient eligibility criteria and endpoint definition. Currently employed AAV vectors may cause toxicity and adverse events. Furthermore, studies in animals do not fully predict risks and clinical benefits of AAV-based GT, and animal models reflecting the heterogeneity of certain clinical settings (e.g., congestive heart failure) are not widely available for improving AAV-based GT. Finally, antisense and gene editing approaches will soon complement gene augmentation strategies for the stable solution of unsolved issues of AAV-based GT. While minimizing toxicity, next-generation AAV vectors should decrease the viral load needed to achieve therapeutic efficacy, be functional in a restricted cellular subset, avoid transgene expression in unwanted cells (e.g., hepatocytes), and escape immune oversight in AAV-based GT. The role of stress-induced apoptosis in the loss of transgene expression in GT should also be explored. Aligning the interests and obligations of the pharmaceutical industry with those of the health system is critical for the success of AAV-based GT. Costs and challenges for the pharmaceutical industry include: a) removing impurities from AAV; b) validating tests to measure treatment efficacy; c) promoting training programs to standardize vector genome delivery; d) collecting long-term follow-up data; and e) maintaining sustainability and cost-effectiveness of AAV-based GT. In rare disorders with small patient numbers (e.g., hemophilia), clear-cut outcomes are mandatory as endpoints of unequivocal efficacy data.<\/jats:p>","DOI":"10.3324\/haematol.2023.284622","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T02:10:59Z","timestamp":1709777459000},"page":"3879-3891","source":"Crossref","is-referenced-by-count":10,"title":["Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies"],"prefix":"10.3324","volume":"109","author":[{"given":"Giovanni","family":"Di Minno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"69376","doi-asserted-by":"crossref","unstructured":"Hacein-Bey-Abina S, Garrigue A, Wang GP. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008; 118(9):3132-3142.","DOI":"10.1172\/JCI35700"},{"key":"69377","doi-asserted-by":"crossref","unstructured":"Raper SE, Chirmule N, Lee FS. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003; 80(1-2):148-158.","DOI":"10.1016\/j.ymgme.2003.08.016"},{"key":"69378","doi-asserted-by":"crossref","unstructured":"Vokinger KN, Avorn J, Kesselheim AS. Sources of innovation in gene therapies - approaches to achieving affordable prices. N Engl J Med. 2023; 388(4):292-295.","DOI":"10.1056\/NEJMp2211729"},{"key":"69379","doi-asserted-by":"crossref","unstructured":"Mendell JR, Al-Zaidy SA, Rodino-Klapac LR. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021; 29(2):464-488.","DOI":"10.1016\/j.ymthe.2020.12.007"},{"key":"69380","doi-asserted-by":"crossref","unstructured":"Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol. 1994; 11(5):517-521.","DOI":"10.1165\/ajrcmb.11.5.7946381"},{"key":"69381","doi-asserted-by":"crossref","unstructured":"High KA. Turning genes into medicines\u2014what have we learned from gene therapy drug development in the past decade?. Nature Communications. 2020; 11(1):5821.","DOI":"10.1038\/s41467-020-19507-0"},{"key":"69382","doi-asserted-by":"crossref","unstructured":"Kuzmin DA, Shutova MV, Johnston NR. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021; 20(3):173-174.","DOI":"10.1038\/d41573-021-00017-7"},{"key":"69383","doi-asserted-by":"crossref","unstructured":"Manno CS, Pierce GF, Arruda VR. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006; 12(3):342-347.","DOI":"10.1038\/nm1358"},{"key":"69384","doi-asserted-by":"crossref","unstructured":"Samelson-Jones BJ, George LA. Adeno-associated virus gene therapy for hemophilia. Annu Rev Med. 2023; 74:231-247.","DOI":"10.1146\/annurev-med-043021-033013"},{"key":"69385","doi-asserted-by":"crossref","unstructured":"Mendell JR, Al-Zaidy S, Shell R. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017; 377(18):1713-1722.","DOI":"10.1056\/NEJMoa1706198"},{"key":"69386","doi-asserted-by":"crossref","unstructured":"Shieh PB, Kuntz NL, Dowling JJ. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial. Lancet Neurol. 2023; 22(12):1125-1139.","DOI":"10.1016\/S1474-4422(23)00313-7"},{"key":"69387","doi-asserted-by":"crossref","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015; 125(4):616-618.","DOI":"10.1182\/blood-2014-11-611335"},{"key":"69388","doi-asserted-by":"crossref","unstructured":"Chand DH, Zaidman C, Arya K. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series. J Pediatr. 2021; 231:265-268.","DOI":"10.1016\/j.jpeds.2020.11.054"},{"key":"69389","doi-asserted-by":"crossref","unstructured":"Salabarria SM, Corti M, Coleman KE. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J Clin Invest. 2024; 134(1):e173510.","DOI":"10.1172\/JCI173510"},{"key":"69390","doi-asserted-by":"crossref","unstructured":"Sondhi D, Kaminsky SM, Hackett NR. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Sci Transl Med. 2020; 12(572)","DOI":"10.1126\/scitranslmed.abb5413"},{"key":"69391","doi-asserted-by":"crossref","unstructured":"Mueller C, Berry JD, McKenna-Yasek DM. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N Engl J Med. 2020; 383(2):151-158.","DOI":"10.1056\/NEJMoa2005056"},{"key":"69392","doi-asserted-by":"crossref","unstructured":"Mullard A. Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov. 2021; 20(4):247-250.","DOI":"10.1038\/d41573-021-00052-4"},{"key":"69393","doi-asserted-by":"crossref","unstructured":"Zu H, Gao D. Non-viral vectors in gene therapy: recent development, challenges, and prospects. AAPS J. 2021; 23(4):78.","DOI":"10.1208\/s12248-021-00608-7"},{"key":"69394","doi-asserted-by":"crossref","unstructured":"Hinderer C, Katz N, Buza EL. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018; 29(3):285-298.","DOI":"10.1089\/hum.2018.015"},{"key":"69395","doi-asserted-by":"crossref","unstructured":"Hordeaux J, Wang Q, Katz N. The neurotropic properties of AAV-PHP.B are limited to C57BL\/6J mice. Mol Ther. 2018; 26(3):664-668.","DOI":"10.1016\/j.ymthe.2018.01.018"},{"key":"69396","doi-asserted-by":"crossref","unstructured":"Keiser MS, Ranum PT, Yrigollen CM. Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain. Nat Med. 2021; 27(11):1982-1989.","DOI":"10.1038\/s41591-021-01522-3"},{"key":"69397","doi-asserted-by":"crossref","unstructured":"Zerah M, Piguet F, Colle MA. Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates. Hum Gene Ther Clin Dev. 2015; 26(2):113-124.","DOI":"10.1089\/humc.2014.139"},{"key":"69398","doi-asserted-by":"crossref","unstructured":"Hordeaux J, Buza EL, Dyer C. Adeno-associated virus-induced dorsal root ganglion pathology. Hum Gene Ther. 2020; 31(15-16):808-818.","DOI":"10.1089\/hum.2020.167"},{"key":"69399","doi-asserted-by":"crossref","unstructured":"Hordeaux J, Buza EL, Jeffrey B. MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates. Sci Transl Med. 2020; 12(569)","DOI":"10.1126\/scitranslmed.aba9188"},{"key":"69400","doi-asserted-by":"crossref","unstructured":"Stone D, Aubert M, Jerome KR. Adeno-associated virus vectors and neurotoxicity-lessons from preclinical and human studies. Gene Ther. 2023.","DOI":"10.1038\/s41434-023-00405-1"},{"key":"69401","doi-asserted-by":"crossref","unstructured":"Morales L, Gambhir Y, Bennett J, Stedman HH. Broader implications of progressive liver dysfunction and lethal sepsis in two boys following systemic high-dose AAV. Mol Ther. 2020; 28(8):1753-1755.","DOI":"10.1016\/j.ymthe.2020.07.009"},{"key":"69402","doi-asserted-by":"crossref","unstructured":"Adachi K, Enoki T, Kawano Y, Veraz M, Nakai H. Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing. Nat Commun. 2014; 5:3075.","DOI":"10.1038\/ncomms4075"},{"key":"69403","doi-asserted-by":"crossref","unstructured":"Earley LF, Conatser LM, Lue VM. Adeno-associated virus serotype-specific inverted terminal repeat sequence role in vector transgene expression. Hum Gene Ther. 2020; 31(3-4):151-162.","DOI":"10.1089\/hum.2019.274"},{"key":"69404","doi-asserted-by":"crossref","unstructured":"Faust SM, Bell P, Cutler BJ. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest. 2013; 123(7):2994-3001.","DOI":"10.1172\/JCI68205"},{"key":"69405","doi-asserted-by":"crossref","unstructured":"Konkle BA, Walsh CE, Escobar MA. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021; 137(6):763-774.","DOI":"10.1182\/blood.2019004625"},{"key":"69406","doi-asserted-by":"crossref","unstructured":"Samaranch L, Sebastian WS, Kells AP. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther. 2014; 22(2):329-337.","DOI":"10.1038\/mt.2013.266"},{"key":"69407","doi-asserted-by":"crossref","unstructured":"Ansari AM, Ahmed AK, Matsangos AE. Cellular GFP toxicity and immunogenicity: potential confounders in in vivo cell tracking experiments. Stem Cell Rev Rep. 2016; 12(5):553-559.","DOI":"10.1007\/s12015-016-9670-8"},{"key":"69408","doi-asserted-by":"crossref","unstructured":"Klein RL, Dayton RD, Leidenheimer NJ. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther. 2006; 13(3):517-527.","DOI":"10.1016\/j.ymthe.2005.10.008"},{"key":"69409","doi-asserted-by":"crossref","unstructured":"Donsante A, Miller DG, Li Y. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007; 317(5837):477.","DOI":"10.1126\/science.1142658"},{"key":"69410","doi-asserted-by":"crossref","unstructured":"Hatada I, Morita S, Obata Y. Identification of a new imprinted gene, Rian, on mouse chromosome 12 by fluorescent differential display screening. J Biochem. 2001; 130(2):187-190.","DOI":"10.1093\/oxfordjournals.jbchem.a002971"},{"key":"69411","doi-asserted-by":"crossref","unstructured":"Chandler RJ, LaFave MC, Varshney GK. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest. 2015; 125(2):870-880.","DOI":"10.1172\/JCI79213"},{"key":"69412","doi-asserted-by":"crossref","unstructured":"Chandler RJ, LaFave MC, Varshney GK, Burgess SM, Venditti CP. Genotoxicity in mice following AAV gene delivery: a safety concern for human gene therapy?. Mol Ther. 2016; 24(2):198-201.","DOI":"10.1038\/mt.2016.17"},{"key":"69413","doi-asserted-by":"crossref","unstructured":"Sun X, Yu X, Zhang L. Comparison of the expression and toxicity of AAV2\/9 carrying the human A53T alpha-synuclein gene in presence or absence of WPRE. Heliyon. 2021; 7(2):e06302.","DOI":"10.1016\/j.heliyon.2021.e06302"},{"key":"69414","doi-asserted-by":"crossref","unstructured":"Hagedorn C, Schnodt-Fuchs M, Boehme P. S\/MAR element facilitates episomal long-term persistence of adeno-associated virus vector genomes in proliferating cells. Hum Gene Ther. 2017; 28(12):1169-1179.","DOI":"10.1089\/hum.2017.025"},{"key":"69415","unstructured":"Powell SK, Rivera-Soto R, Gray SJ. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov Med. 2015; 19(102):49-57."},{"key":"69416","doi-asserted-by":"crossref","unstructured":"Favre D, Blouin V, Provost N. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J Virol. 2002; 76(22):11605-11611.","DOI":"10.1128\/JVI.76.22.11605-11611.2002"},{"key":"69417","doi-asserted-by":"crossref","unstructured":"Kondratova L, Kondratov O, Ragheb R, Zolotukhin S. Removal of endotoxin from rAAV samples using a simple detergent-based protocol. Mol Ther Methods Clin Dev. 2019; 15:112-119.","DOI":"10.1016\/j.omtm.2019.08.013"},{"key":"69418","doi-asserted-by":"crossref","unstructured":"Schnodt M, Buning H. Improving the quality of adeno-associated viral vector preparations: the challenge of product-related impurities. Hum Gene Ther Methods. 2017; 28(3):101-108.","DOI":"10.1089\/hgtb.2016.188"},{"key":"69419","doi-asserted-by":"crossref","unstructured":"Wright JF. Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare?. Mol Ther. 2020; 28(3):701-703.","DOI":"10.1016\/j.ymthe.2020.01.026"},{"key":"69420","doi-asserted-by":"crossref","unstructured":"Perez BA, Shutterly A, Chan YK, Byrne BJ, Corti M. Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci. 2020; 10(2):119.","DOI":"10.3390\/brainsci10020119"},{"key":"69421","doi-asserted-by":"crossref","unstructured":"Hordeaux J, Hinderer C, Goode T. Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing iduronate-2-sulfatase in rhesus macaques. Mol Ther Methods Clin Dev. 2018; 10:68-78.","DOI":"10.1016\/j.omtm.2018.06.004"},{"key":"69422","doi-asserted-by":"crossref","unstructured":"Hordeaux J, Hinderer C, Goode T. Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-iduronidase in rhesus macaques. Mol Ther Methods Clin Dev. 2018; 10:79-88.","DOI":"10.1016\/j.omtm.2018.06.003"},{"key":"69423","doi-asserted-by":"crossref","unstructured":"Bertolini TB, Shirley JL, Zolotukhin I. Effect of CpG depletion of vector genome on CD8(+) T cell responses in AAV gene therapy. Front Immunol. 2021; 12:672449.","DOI":"10.3389\/fimmu.2021.672449"},{"key":"69424","doi-asserted-by":"crossref","unstructured":"Chan YK, Wang SK, Chu CJ. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci Transl Med. 2021; 13(580):eabd3438.","DOI":"10.1126\/scitranslmed.abd3438"},{"key":"69425","doi-asserted-by":"crossref","unstructured":"Xiang Z, Kurupati RK, Li Y. The effect of CpG sequences on capsid-specific CD8(+) T cell responses to AAV vector gene transfer. Mol Ther. 2020; 28(3):771-783.","DOI":"10.1016\/j.ymthe.2019.11.014"},{"key":"69426","doi-asserted-by":"crossref","unstructured":"Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol. 2020; 21(8):421-438.","DOI":"10.1038\/s41580-020-0250-z"},{"key":"69427","doi-asserted-by":"crossref","unstructured":"Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia A gene therapy: current and next-generation approaches. Expert Opin Biol Ther. 2022; 22(9):1099-1115.","DOI":"10.1080\/14712598.2022.2002842"},{"key":"69428","doi-asserted-by":"crossref","unstructured":"Ghemrawi R, Khair M. Endoplasmic reticulum stress and unfolded protein response in neurodegenerative diseases. Int J Mol Sci. 2020; 21(17)","DOI":"10.3390\/ijms21176127"},{"key":"69429","doi-asserted-by":"crossref","unstructured":"Prasad V, Greber UF. The endoplasmic reticulum unfolded protein response - homeostasis, cell death and evolution in virus infections. FEMS Microbiol Rev. 2021; 45(5):fuab016.","DOI":"10.1093\/femsre\/fuab016"},{"key":"69430","doi-asserted-by":"crossref","unstructured":"Buss N, Lanigan L, Zeller J. Characterization of AAV-mediated dorsal root ganglionopathy. Mol Ther Methods Clin Dev. 2022; 24:342-354.","DOI":"10.1016\/j.omtm.2022.01.013"},{"key":"69431","doi-asserted-by":"crossref","unstructured":"Chung DC, McCague S, Yu ZF. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol. 2018; 46(3):247-259.","DOI":"10.1111\/ceo.13022"},{"key":"69432","doi-asserted-by":"crossref","unstructured":"Bennett J, Maguire AM. Lessons learned from the development of the first FDA-approved gene therapy drug, voretigene neparvovec-rzyl. Cold Spring Harb Perspect Med. 2023; 13(5):a041307.","DOI":"10.1101\/cshperspect.a041307"},{"key":"69433","doi-asserted-by":"crossref","unstructured":"Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. 2017; 9(6):737-740.","DOI":"10.15252\/emmm.201707573"},{"key":"69434","doi-asserted-by":"crossref","unstructured":"Makris M. Hemophilia gene therapy is effective and safe. Blood. 2018; 131(9):952-953.","DOI":"10.1182\/blood-2018-01-824144"},{"key":"69435","doi-asserted-by":"crossref","unstructured":"Miesbach W, Foster GR, Peyvandi F. Liver-related aspects of gene therapy for hemophilia: need for collaborations with hepatologists. J Thromb Haemost. 2023; 21(2):200-203.","DOI":"10.1016\/j.jtha.2022.11.026"},{"key":"69436","doi-asserted-by":"crossref","unstructured":"Leung PB, Davis AM, Kumar S. Diagnosis and management of nonalcoholic fatty liver disease. JAMA. 2023; 330(17):1687-1688.","DOI":"10.1001\/jama.2023.17935"},{"key":"69437","doi-asserted-by":"crossref","unstructured":"Rietveld IM, Lijfering WM, le Cessie S. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost. 2019; 17(1):99-109.","DOI":"10.1111\/jth.14343"},{"key":"69438","doi-asserted-by":"crossref","unstructured":"Di Minno G, Castaman G, De Cristofaro R. Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy. Blood Rev. 2023; 58:101011.","DOI":"10.1016\/j.blre.2022.101011"},{"key":"69439","doi-asserted-by":"crossref","unstructured":"Pierce GF, Iorio A. Past, present and future of haemophilia gene therapy: from vectors and transgenes to known and unknown outcomes. Haemophilia. 2018; 24(Suppl 6):60-67.","DOI":"10.1111\/hae.13489"},{"key":"69440","doi-asserted-by":"crossref","unstructured":"Naso MF, Tomkowicz B, Perry WL, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017; 31(4):317-334.","DOI":"10.1007\/s40259-017-0234-5"},{"key":"69441","doi-asserted-by":"crossref","unstructured":"Soni S. Gene therapies for transfusion dependent beta-thalassemia: current status and critical criteria for success. Am J Hematol. 2020; 95(9):1099-1112.","DOI":"10.1002\/ajh.25909"},{"key":"69442","doi-asserted-by":"crossref","unstructured":"Thuret I, Ruggeri A, Angelucci E, Chabannon C. Hurdles to the adoption of gene therapy as a curative option for transfusiondependent thalassemia. Stem Cells Transl Med. 2022; 11(4):407-414.","DOI":"10.1093\/stcltm\/szac007"},{"key":"69443","doi-asserted-by":"crossref","unstructured":"Keeler AM, Flotte TR. Recombinant adeno-associated virus gene therapy in light of luxturna (and Zolgensma and Glybera): where are we, and how did we get here?. Annu Rev Virol. 2019; 6(1):601-621.","DOI":"10.1146\/annurev-virology-092818-015530"},{"key":"69444","doi-asserted-by":"crossref","unstructured":"Schmidt M, Foster GR, Coppens M. Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B. Blood Adv. 2023; 7(17):4966-4969.","DOI":"10.1182\/bloodadvances.2023009876"},{"key":"69445","unstructured":"Consortium EH. BioMarin announced an additional serious adverse event in its gene therapy clinical trial for haemophilia A. 2022."},{"key":"69446","doi-asserted-by":"crossref","unstructured":"Nguyen GN, Everett JK, Kafle S. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021; 39(1):47-55.","DOI":"10.1038\/s41587-020-0741-7"},{"key":"69447","doi-asserted-by":"crossref","unstructured":"Greig JA, Martins KM, Breton C. Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration. Nat Biotechnol. 2024; 42:1232-1242.","DOI":"10.1038\/s41587-023-01974-7"},{"key":"69448","doi-asserted-by":"crossref","unstructured":"Bryant LM, Christopher DM, Giles AR. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev. 2013; 24(2):55-64.","DOI":"10.1089\/humc.2013.087"},{"key":"69449","doi-asserted-by":"crossref","unstructured":"Nathwani AC, Tuddenham EG, Rangarajan S. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011; 365(25):2357-65.","DOI":"10.1056\/NEJMoa1108046"},{"key":"69450","doi-asserted-by":"crossref","unstructured":"Ertl HCJ. T cell-mediated immune responses to AAV and AAV vectors. Front Immunol. 2021; 12:666666.","DOI":"10.3389\/fimmu.2021.666666"},{"key":"69451","doi-asserted-by":"crossref","unstructured":"Herzog RW. Complexity of immune responses to AAV transgene products - example of factor IX. Cell Immunol. 2019; 342:103658.","DOI":"10.1016\/j.cellimm.2017.05.006"},{"key":"69452","doi-asserted-by":"crossref","unstructured":"Muhuri M, Maeda Y, Ma H. Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest. 2021; 131(1):e143780.","DOI":"10.1172\/JCI143780"},{"key":"69453","doi-asserted-by":"crossref","unstructured":"George LA, Sullivan SK, Giermasz A. Hemophilia B gene therapy with a high-specific-activity Factor IX variant. 2017; 377(23):2215-2227.","DOI":"10.1056\/NEJMoa1708538"},{"key":"69454","doi-asserted-by":"crossref","unstructured":"Rangarajan S, Walsh L, Lester W. AAV5\u2013Factor VIII gene transfer in severe hemophilia A. 2017; 377(26):2519-2530.","DOI":"10.1056\/NEJMoa1708483"},{"key":"69455","doi-asserted-by":"crossref","unstructured":"Pierce GF. Uncertainty in an era of transformative therapy for haemophilia: addressing the unknowns. Haemophilia. 2021; 27(Suppl 3):103-113.","DOI":"10.1111\/hae.14023"},{"key":"69456","doi-asserted-by":"crossref","unstructured":"Miesbach W, Meijer K, Coppens M. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 20181; 131(9):1022-1031.","DOI":"10.1182\/blood-2017-09-804419"},{"key":"69457","doi-asserted-by":"crossref","unstructured":"Nathwani AC, Rosales C, McIntosh J. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011; 19(5):876-885.","DOI":"10.1038\/mt.2010.274"},{"key":"69458","doi-asserted-by":"crossref","unstructured":"Pasi KJ, Rangarajan S, Mitchell N. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med. 2020; 382(1):29-40.","DOI":"10.1056\/NEJMoa1908490"},{"key":"69459","doi-asserted-by":"crossref","unstructured":"Fong S, Yates B, Sihn CR. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. Nat Med. 2022; 28(4):789-797.","DOI":"10.1038\/s41591-022-01751-0"},{"key":"69460","doi-asserted-by":"crossref","unstructured":"Pillay S, Meyer NL, Puschnik AS. An essential receptor for adeno-associated virus infection. Nature. 2016; 530(7588):108-112.","DOI":"10.1038\/nature16465"},{"key":"69461","doi-asserted-by":"crossref","unstructured":"Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011; 30(1):16-34.","DOI":"10.3109\/08830185.2010.529976"},{"key":"69462","doi-asserted-by":"crossref","unstructured":"Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006; 13(5):816-825.","DOI":"10.1038\/sj.cdd.4401850"},{"key":"69463","doi-asserted-by":"crossref","unstructured":"Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2015; 109:14.12.1-14.12.10.","DOI":"10.1002\/0471142735.im1412s109"},{"key":"69464","doi-asserted-by":"crossref","unstructured":"Cannata A, Ali H, Sinagra G, Giacca M. Gene therapy for the heart lessons learned and future perspectives. Circ Res. 2020; 126(10):1394-1414.","DOI":"10.1161\/CIRCRESAHA.120.315855"},{"key":"69465","doi-asserted-by":"crossref","unstructured":"Adair JE, Androski L, Bayigga L. Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Gene Therapy. 2023; 30(3):216-221.","DOI":"10.1038\/s41434-021-00284-4"},{"key":"69466","doi-asserted-by":"crossref","unstructured":"Chen H, Shi M, Gilam A. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII. Sci Rep. 2019; 9(1):16838.","DOI":"10.1038\/s41598-019-53198-y"},{"key":"69467","unstructured":"Ponomarev AS, Chulpanova DS, Yanygina LM, Solovyeva VV, Rizvanov AA. Emerging gene therapy approaches in the management of spinal muscular atrophy (SMA): an overview of clinical trials and patent landscape. Int J Mol Sci. 2021; 131(1):e143780."},{"key":"69468","unstructured":"Targeted gene insertion of Factor 9 as a potential durable treatment for hemophilia B. CRISPR\/Cas9-mediated F9 gene insertion therapy \/ Intellia Therap, Regeneron - LARVOL DELTA. 2023."},{"key":"69469","unstructured":"Johnson V. First patient with hemophilia A dosed in new gene therapy trial. 2023."},{"key":"69470","doi-asserted-by":"crossref","unstructured":"Lek A, Wong B, Keeler A. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N Engl J Med. 2023; 389(13):1203-1210.","DOI":"10.1056\/NEJMoa2307798"},{"key":"69471","doi-asserted-by":"crossref","unstructured":"Skinner MW, Nugent D, Wilton P. Achieving the unimaginable: health equity in haemophilia. Haemophilia. 2020; 26(1):17-24.","DOI":"10.1111\/hae.13862"},{"key":"69472","doi-asserted-by":"crossref","unstructured":"Lambert C, Meite N, Sanogo I. Haemophilia in Cote d\u2019Ivoire (the Ivory Coast) in 2017: extensive data collection as part of the World Federation of Hemophilia\u2019s twinning programme. Haemophilia. 2019; 25(2):236-243.","DOI":"10.1111\/hae.13682"},{"key":"69473","doi-asserted-by":"crossref","unstructured":"High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019; 381(5):455-464.","DOI":"10.1056\/NEJMra1706910"},{"key":"69474","doi-asserted-by":"crossref","unstructured":"Di Minno G, Tremoli E. Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine. Haematologica. 2017; 102(3):411-418.","DOI":"10.3324\/haematol.2016.156000"},{"key":"69475","doi-asserted-by":"crossref","unstructured":"Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med. 2001; 344(23):1773-1779.","DOI":"10.1056\/NEJM200106073442307"},{"key":"69476","doi-asserted-by":"crossref","unstructured":"Ozelo MC, Mahlangu J, Pasi KJ. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022; 386(11):1013-1025.","DOI":"10.1056\/NEJMoa2113708"},{"key":"69477","doi-asserted-by":"crossref","unstructured":"Visweshwar N, Harrington TJ, Leavitt AD. Updated results of the Alta study, a phase 1\/2 study of giroctocogene fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia a. Blood. 2021; 138:564.","DOI":"10.1182\/blood-2021-148651"},{"key":"69478","doi-asserted-by":"crossref","unstructured":"George LA, Monahan PE, Eyster ME. Multiyear Factor VIII expression after AAV gene transfer for hemophilia A. N Engl J Med. 2021; 385(21):1961-1973.","DOI":"10.1056\/NEJMoa2104205"},{"key":"69479","doi-asserted-by":"crossref","unstructured":"Von Drygalski A, Giermasz A, Castaman G. Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019; 3(21):3241-3247.","DOI":"10.1182\/bloodadvances.2019000811"},{"key":"69480","doi-asserted-by":"crossref","unstructured":"Chowdary P, Hamid C, Slatter D. Impaired platelet-dependent thrombin generation associated with thrombocytopenia is improved by prothrombin complex concentrates in vitro. Res Pract Thromb Haemost. 2020; 4(2):334-342.","DOI":"10.1002\/rth2.12310"},{"key":"69481","doi-asserted-by":"crossref","unstructured":"Feldman AG, Parsons JA, Dutmer CM. Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1. J Pediatr. 2020; 225:252-258.e1.","DOI":"10.1016\/j.jpeds.2020.05.044"},{"key":"69482","unstructured":"FDA. Cellular Tissue and Gene Therapies Advisory Committee (CTGTAC) Meeting #70 September 2-3. 2021."},{"key":"69483","doi-asserted-by":"crossref","unstructured":"High-dose AAV gene therapy deaths. Nature Biotechnology. 2020; 38(8):910-910.","DOI":"10.1038\/s41587-020-0642-9"},{"key":"69484","doi-asserted-by":"crossref","unstructured":"Mullard A. Gene therapy community grapples with toxicity issues, as pipeline matures. Nat Rev Drug Discov. 2021; 20(11):804-805.","DOI":"10.1038\/d41573-021-00164-x"},{"key":"69485","unstructured":"Pharmaceuticals R. Rocket pharmaceuticals announces positive updates from phase 1 clinical trial of RP-A501 in Danon disease. 2021."},{"key":"69486","unstructured":"FDA. FDA Lifts Clinical Hold on LogicBio\u2019s Pediatric Trial. 2022."},{"key":"69487","unstructured":"Sherafat R. Toxicity risks of adeno-associated virus (AAV) vectors for gene therapy (GT). FDA. 2021."},{"key":"69488","unstructured":"Bonnemann C. Virtual workshop on systemic immunogenicity considerations of AAV-mediated gene therapy. NIH. 2020."},{"key":"69489","unstructured":"Pfizer\/Sangamo.Pfizer\/Sangamo Therapeutics report severe adverse event (SAE) from phase 3 AFFINE haemophilia A gene therapy study. 2022."},{"key":"69490","doi-asserted-by":"crossref","unstructured":"Philippidis A. Pfizer eyes resuming phase III enrollment, investigates phase Ib death tied to Duchenne muscular dystrophy candidate. 2022; 33(5-6):215-217.","DOI":"10.1089\/hum.2022.29203.bfs"},{"key":"69491","doi-asserted-by":"crossref","unstructured":"Monteys AM, Hundley AA, Ranum PT. Regulated control of gene therapies by drug-induced splicing. Nature. 2021; 596(7871):291-295.","DOI":"10.1038\/s41586-021-03770-2"},{"key":"69492","doi-asserted-by":"crossref","unstructured":"Domenger C, Grimm D. Next-generation AAV vectors-do not judge a virus (only) by its cover. Hum Mol Genet. 2019; 28(R1):R3-R14.","DOI":"10.1093\/hmg\/ddz148"},{"key":"69493","doi-asserted-by":"crossref","unstructured":"Buning H, Srivastava A. Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol Ther Methods Clin Dev. 2019; 12:248-265.","DOI":"10.1016\/j.omtm.2019.01.008"},{"key":"69494","doi-asserted-by":"crossref","unstructured":"Stone D, Aubert M, Jerome KR. Adeno-associated virus sectors and neurotoxicity-lessons from preclinical and human studies. Gene Ther. 2023.","DOI":"10.1038\/s41434-023-00405-1"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284622\/76730","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284622\/77827","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11496\/76730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:55Z","timestamp":1794045955000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":119,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284622","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}